Is Insmed Incorporated (INSM) Favorite Among The Institutional Crowd?

Insmed Incorporated (NASDAQ:INSM) is on recovery track with 82.58% gain from a 1-year low price of $11.31. The company lost -5.1% to attain the price of $20.65 on 01/09/2019. Throughout the recent session, the prices were hovering between $20.12 and $21.93. These shares are 77.05% off its target price of $36.56 and the current market capitalization stands at $1.59B. The recent change has given its price a 30.2% lead over SMA 50 and -35.61% deficit over its 52-week high. The stock witnessed 31.03% gains, 22.04% gains and -17.93% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found INSM’s volatility during a week at 9.93% and during a month it has been found around 8.24%.

Insmed Incorporated (INSM) Top Holders

Institutional investors currently hold around $1.75 billion or 0% in INSM stock. Look at its top three institutional owners. Fmr Llc owns $251.46 million in Insmed Incorporated, which represents roughly 15.82% of the company’s market cap and approximately 14.35% of the institutional ownership. Similar statistics are true for the second largest owner, Price T Rowe Associates Inc /Md/, which owns 10,500,244 shares of the stock are valued at $228.49 million. The third largest holder is Janus Henderson Group Plc, which currently holds $202.48 million worth of this stock and that ownership represents nearly 12.73% of its market capitalization.

Insmed Incorporated 13F Filings

At the end of September reporting period, 56 institutional holders increased their position in Insmed Incorporated (NASDAQ:INSM) by some 7,293,528 shares, 63 decreased positions by 8,474,993 and 25 held positions by 64,757,636. That puts total institutional holdings at 80,526,157 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 1,331,645 shares while 22 institutional investors sold out their entire positions totaling 3,480,951 shares.

Insmed Incorporated (NASDAQ:INSM) Insider Trades

Multiple company employees have indulged in significant insider trading. Insmed Incorporated disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Sharoky Melvin Md has acquired 20,000 shares of Insmed Incorporated (INSM) in trading session dated Nov. 12, 2018. These shares are worth $320,200 and were traded at $16.01 each. The SEC filing shows that Lewis William performed a purchase of 15,700 shares. The President & CEO added these shares by way of transaction on Nov. 01, 2018. The company’s shares were assimilated at $15.9 per share worth to an investment of some $249,630 on account of Lewis William.

Chief Commercial Officer, Adsett Roger, purchased 3,000 common shares of Insmed Incorporated (INSM) in the open market. In a transaction dated Nov. 01, 2018, the shares were bought at an average price of $15.97, giving away a sum of $47,910. After this purchase, 18,594 common shares of INSM are directly owned by the insider, with total stake valued at $383,966.

In the transaction dated Nov. 01, 2018, the great number of shares acquired came courtesy the Director; Engelsen Steinar J added a total of 16,085 shares at an average price of $15.79, amounting to approximately $253,982. The insider now directly owns 281,303 shares worth $5,808,907.

Insmed Incorporated (INSM) Analyst Guide

Several analysts have released their opinion on Insmed Incorporated (NASDAQ:INSM), with 3 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.